MucoLife Therapeutics develops a mucolytic agent that effectively dissolves mucus plugs obstructing airways in patients with Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis (CF). This targeted treatment addresses the critical issue of mucus obstruction, improving respiratory function and patient quality of life.
Funding
$30K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis (CF) suffer from mucus plugs obstructing airways, which impairs respiratory function and reduces quality of life. Current treatments do not effectively dissolve these mucus plugs.
Solution
MucoLife Therapeutics is developing a mucolytic agent designed to dissolve mucus plugs obstructing airways in patients with COPD and CF. This targeted treatment aims to improve respiratory function by directly addressing the issue of mucus obstruction. The company's lead product is a true mucolytic, offering a novel approach to clearing airways.
Target Audience
The primary target audience includes patients with Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis (CF) who experience airway obstruction due to mucus plugs.
Features
- Mucolytic agent specifically designed to dissolve mucus plugs.
- Targeted treatment for pulmonary mucus obstruction.
- Focus on improving respiratory function in COPD and CF patients.